Carl Zeiss AG
http://www.zeiss.de
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Carl Zeiss AG
BTIG Analyst Zooms Into Alcon’s Revamp Into ‘Building A Pharma Company Inside A Device Company’
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Start-Up Spotlight: Vivior's Wearable Eye Monitor Seeks To Sharpen Vision Correction
Swiss-based Vivior AG has developed a wearable Visual Behavior Monitor (VBM) designed to help surgical ophthalmologists determine the best treatment options for patients. The company's initial target is the $2.15bn global refractive and cataract surgery market.
M&A Analysis: August Activity Cools As The Summer Closes
Medtech M&A activity slowed in the last month of summer with just 16 mergers and acquisitions recorded on the Medtech Insight M&A Deal Tracker. However, the month included one billion-dollar deal and several deals in the ophthalmological sector.
OcuSciences Inc.
OcuSciences Inc.'s OcuMet Beacon is a noninvasive and rapid diagnostic screening tool for retinal disease. The current ophthalmic standard of care, optical coherence tomography, evaluates structural change in retinal thickness or swelling after retinal damage has occurred, but OcuMet can provide a level of functional testing before damage occurs, which is especially important for latent diabetics or patients undiagnosed for retinal diseases.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Carl Zeiss AG are: Carl Zeiss Meditec AG, Carl Zeiss Vision GmbH, Carl Zeiss SMT GmbH, Carl Zeiss IMT GmbH, Carl Zeiss Microscopy GmbH.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice